Source of stem cell rescue: bone marrow versus peripheral blood progenitors.
Sustained hematopoiesis can be restored after dose-intensive chemotherapy utilizing stem cells from either bone marrow and/or peripheral blood. Numerous reports have demonstrated the effectiveness of peripheral blood progenitors (PBPC) in restoring hematopoiesis. Here, we review data comparing the recovery among patients rescued with various stem cell sources after dose-intensive therapy. PBPC used alone or to augment autologous bone marrow to achieve timely hematopoietic recovery after dose-intensive therapy can result in shortened hospital stays, decreased transfusion requirements, and antibiotic usage. This will lead to increased application of dose-intensive therapy either singly or in multiple courses to treat various malignancies.
Williams
S F
SF
Department of Medicine, University of Chicago Medical Center, IL 60637.
Zimmerman
T
T
Grad
G
G
Mick
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001773:Blood Cells; D001804:Blood Transfusion, Autologous; D001854:Bone Marrow Cells; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D002641:Chicago / Q000453:epidemiology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006410:Hematopoiesis / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007937:Leukapheresis; D012189:Retrospective Studies; D016019:Survival Analysis; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects
D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D013852:Thiotepa